HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Income Statement
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.46M | 2.09M | 900.00K | 3.10M | 175.00K | |||
| Cost Of Goods | 227.00K | 93.00K | 94.00K | 107.00K | 145.00K | |||
| Gross Profit | 8.23M | 1.99M | 806.00K | 2.99M | 30.00K | |||
| Operating Expenses | 14.60M | 17.84M | 12.31M | 13.32M | 5.11M | |||
| Research and Development | 10.27M | 14.42M | 10.27M | 5.03M | 2.93M | |||
| Selling, General, and Administrative Expenses | 5.63M | 5.55M | 3.52M | 2.90M | 2.19M | |||
| Operating Income | -6.37M | -15.85M | -11.51M | -10.33M | -5.08M | |||
| Interest Income/Expense | -214.00K | 514.00K | -102.00K | -715.00K | -2.02M | |||
| Other Income/Expense | -51.00K | -48.00K | -291.00K | -217.00K | 433.00K | |||
| Non Recurring Items | 292.00K | N/A | N/A | -23.00K | -480.00K | |||
| Income Before Taxes | -6.34M | -15.38M | -11.90M | -11.28M | -7.14M | |||
| Income Tax | 0.00 | 0.00 | 4.00K | 297.00K | 1.00K | |||
| Net Income | -6.34M | -15.38M | -11.91M | -11.58M | -7.14M | |||
| EBITDA | -5.72M | -15.50M | -11.31M | -10.19M | -4.50M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.23 | -0.55 | -0.44 | -0.45 | -0.33 | |||
| Statistics | ||||||||
| Gross Profit Margin | 97.32% | 95.54% | 89.56% | 96.54% | 17.14% | |||
| Profit Margin | -74.98% | -736.94% | -1322.89% | -374.00% | -4082.86% | |||
| Operating Profit Margin | -75.30% | -759.27% | -1278.67% | -333.56% | -2901.14% | |||
All data in EUR